Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

European Research Council grant · Running

Q-MIND Quantitative neuroiMaging In early Neurodegenerative Disease

Coordinator
The University of Nottingham, United Kingdom
Runs
1 January 2027 to 30 June 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101334762

What the project is doing

In the project's own words, from its summary on CORDIS.

Neurodegenerative diseases, including Alzheimer’s disease (AD), pose a major global health and economic challenge, with over 10 million new cases annually and costs exceeding $1.3 trillion. As the first AD-modifying therapies emerge, their effectiveness depends on identifying the right patients at the appropriate stage. However, current diagnostic and clinical trial-support tools, such as PET scans and lumbar punctures, are costly, poorly scalable and have safety risks.

This impairs patient stratification and trial efficiency, and delays diagnosis until significant neuronal loss has occurred, limiting treatment impact. We are developing a quantitative toolkit to enable early detection of AD-related brain changes, before irreversible clinical symptoms develop, allowing timely interventions that prevent disease progression. Our platform transforms routine, widely accessible Magnetic Resonance Imaging (MRI) scans into personalised, population-referenced markers of brain health, building on over a decade of research in advanced brain MRI analytics.

Using AI-driven normative models, our approach supports better patient stratification, including selection of individuals likely to respond to therapy, thus improving clinical trial outcomes, and enable early diagnosis. Within this proof-of-concept, we will: i) consolidate MRI-derived markers of early AD, building upon our pilot evidence, ii) benchmark them against PET and evaluate their predictive power for progressive AD phenotypes, iii) independently validate their performance through industry & clinical partners, iv) devise a commercialisation plan through planned market research.

Utilising existing industry links, we will initially focus on enhancing patient selection for AD clinical trials, building the evidence base for regulatory approval and clinical translation. Ultimately, our toolset will be productised to allow emerging clinical care pathways to be optimised, improving patient outcomes and healthcare economics.

Who is involved

OrganisationCityCountryRole
The University of NottinghamNottinghamUnited KingdomCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS